• Global Genome Sharing Alliance Launched

    Nature News | A consortium of 69 institutions in 13 countries plans to work to enable the free flow of information in genomic medicine by developing standards and policies to encourage data-sharing of a person’s DNA sequence combined with clinical information.

    Jun 6, 2013

  • Searching for Gold: GSK’s New Search Program that Saved Them Millions

    Bio-IT World Best Practices | In 2011, the leadership in the GlaxoSmithKline’s R&D department made a troubling realization: their scientists were having a tough time finding their data. R&D engineers set about building a new search program that could search through the company’s archived electronic lab notebooks and recognize a vast library of scientific terms. The program’s capabilities earned GSK the 2013 Best Practices Award for Knowledge Management at the Bio-IT World Expo in April.

    Jun 5, 2013

  • Dell Launches Clinical Genomics Infrastructure

    Bio-IT World | Dell announced today the Dell Active Infrastructure for HPC Life Sciences, an infrastructure system optimized for genomic research to begin shipping in July.

    Jun 4, 2013

  • Microsoft CIO Leaves Company

    Computerworld | Microsoft CIO Tony Scott has left the company. The news was circulating thanks to Scott's LinkedIn profile and the company's senior leader webpage before Microsoft released an announcement.

    Jun 4, 2013

  • The Data Copy Issue

    Computerworld | Not only do we have a lot of data, we have many copies of the same data. Created for backup, or research, or sharing, all that duplication is getting out of hand, analysts say.

    Jun 4, 2013

  • Research and the Public Cloud: Potential and Pitfalls

    Bio-IT World | SINGAPORE—Jumping on the public cloud bandwagon could go a long way toward alleviating data storage, retrieval and archival woes currently experienced by the research industry, said Chris Dagdigian, founding partner and director of technology, The BioTeam. Dagdigian gave his annual “Trends from the Trenches” keynote address at Bio-IT World Asia last week in Singapore.

    Jun 3, 2013

  • Stapled Peptides: Targeting the “Undruggable”

    Bio-IT World | SINGAPORE—Sir David Lane kicked off the 2013 Bio-IT World Asia conference this week by describing an alternative paradigm for drug discovery and development: using stapled peptides to target protein-protein interactions.

    May 30, 2013

  • Amazon Releases API for Google, Facebook Sign-In

    Computerworld | Amazon Web Services is integrating its login process with Amazon.com, Facebook and Google. Amazon calls the concept web identity federation, and released a new AWS Security Token Service (STS) API to simplify the development process.

    May 30, 2013

  • Researchers Characterize Chemical Structure of HIV Capsid

    Bio-IT World | Today researchers at the University of Illinois at Urbana- Champaign have announced the discovery of the chemical structure of the capsid for the HIV virus. The discovery was facilitated by the Blue Waters supercomputer system at the National Center for Supercomputing Applications (NCSA), and is published this week in Nature.

    May 28, 2013

  • Valeant Pharma Buys Bausch & Lomb

    New York Times Dealbook | Valeant Pharmaceuticals International of Canada has purchased Bausch & Lomb, the eye care company, for about $8.7 billion.

    May 27, 2013

  • Transforming Your Business Defined

    Bio-IT World | Guest Commentary | Transform your business before it’s transformed for you. These words convey a hard truth about modern business—external forces are rapidly conspiring to unravel even the best-laid plans. From geopolitical and economic macro trends to global threats to health and the environment, business change is now maddeningly unpredictable and capricious. Absent a proactive plan to address these new business realities, some businesses are in for challenging futures.

    May 27, 2013

  • Too Much to Ignore: Anne Wojcicki’s Plan for Health Care and Big Data

    Bio-IT World | STANFORD, CA—The challenge in healthcare is to change what is—and what isn’t—a billable question, said 23andMe founder Ann Wojcicki, giving the opening keynote yesterday at the Big Data in Biomedicine conference at Stanford University. And they key will be generating so much data that we’re forced to figure it out.

    May 23, 2013

  • PatientsLikeMe Launches Open Research Platform

    InformationWeek | PatientsLikeMe has launched its Open Research Exchange and issued a call for patients, an initiative funded by a Robert Wood Johnson Foundation grant announced earlier this year.

    May 23, 2013

  • US the Least Risky Spot for Your Data Center

    Computerworld | An survey of 30 countries finds the US to be the least risky place to open a data center, followed by the UK, Germany and Sweden. The most risky spots were Indonesia, India, and Brazil.

    May 23, 2013

  • CPT Code Concerns Raise Issues for Diagnostics Industry

    Bio-IT World | With the plummeting cost of next-generation sequencing (NGS) expanding the range of clinical genomics tests being offered by diagnostics companies and medical centers, a looming problem lies in reimbursement.

    May 21, 2013

  • The Gene Test Question

    New York Times | Angelina Jolie announced drastic action this week--a preventive double mastectomy after learning that she carries a faulty copy of BRCA1. But this type of action isn't available to all women, thanks to the high costs of gene tests.

    May 21, 2013

  • Speed in the Consumer Cloud

    ReadWrite Cloud | ReadWrite tests the speed of the top file-transfer/file-storage/file-backup services: Dropbox, Google Drive, Amazon Cloud, and Microsoft’s SkyDrive.

    May 20, 2013

  • Big R&D Spenders: Pharma and Chips

    In the Pipeline | Derek Lowe breaks down how much various companies and sectors spend on R&D. The big spenders? Drug discovery and semiconductor companies.

    May 20, 2013

  • The Elusive Exascale

    HPC Wire | Horst Simon believes we won’t be achieving exascale computing any time soon.

    May 17, 2013

  • BMS Set to Win on Cancer Combinations

    Forbes | Bristol-Myers Squibb's approved drug, Yervoy, is being tested in combination with several experimental drugs to treat advanced melanoma.

    May 16, 2013